The discussion regarding the establishment of the minimum quantity requirements for the surgical treatment of lung and breast cancer was initiated by the Federal Joint Committee (G-BA) in July of 2018

14

Sep 2018

In July of 2018, the Federal Joint Committee (G-BA) has initiated the discussion regarding the establishment of the minimum quantity requirements for the following procedures:

  • The surgical treatment of breast cancer;
  • The surgical treatment of bronchial carcinoma.

As the quality of surgery is directly dependent on the quantity, more specifically, on the number of operations performed at a given hospital as well as on the designated surgeon, the main aim is to understand the importance of the experience and routine practice of lung and breast cancer operations to reach the successful treatment outcomes and to determine the minimum number of operations, which should be performed in hospitals to gain enough experience.

Nowadays, the minimum quantity requirements are established by G-BA in accordance with §136b SGB V for the following procedures:

  • Liver transplantation (including living organ donation)
  • Kidney transplantation (including living organ donation)
  • Complex interventions on the digestive system (esophagus)
  • Complex interventions on pancreas
  • Stem cell transplantation
  • Total knee replacement (total endoprosthesis, TEP)
  • Care of premature and newborns of very low birth weight (less than 1250 grams)

See full details in German here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

22

Mar 2022

On February 17, 2022, the Federal Joint Committee (G-BA) has decided to include the method of matrix-associated autologous chondrocyte implantation (M-ACI) on the knee joint in the case of symptomatic cartilage damage in the lists of reimbursed procedures in the hospital and ambulatory settings.

Read more

09

Mar 2022

On February 16, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) has published the decisions which recommended the transfer to standard care for three completed projects. The projects relate to the prevention of antibiotic resistance, improvement of healthcare in socially disadvantaged areas, and misuse of control colonoscopies in Germany.

Read more

03

Mar 2022

In February 2022, two more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, thirty health apps are now available at the DiGA Directory.

Read more

07

Feb 2022

On January 20, 2022, the Federal Joint Committee (G-BA) has initiated an evaluation procedure for early benefit assessment for the use of a stent retriever (pRELAX by femtos) to treat vasospasm of cerebral arteries after subarachnoid hemorrhage.

Read more

28

Jan 2022

On December 26, 2021, the new health app was introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, 28 health apps are now available at the DiGA Directory.

Read more